Clearance for Quidel's QuickVue allergy test:
This article was originally published in Clinica
Executive Summary
Quidel (US) has gained FDA market clearance for its QuickVue One-Step Allergen Screen, which distinguishes allergy symptoms such as rhinitis, wheezing, hives and skin rashes from viral or bacterial infections such as colds and 'flu. Performed using a small blood sample from either a finger prick or venipuncture, it is claimed to be the first in-office, one-step allergy test to allow primary-care screening for five common indoor allergens in 15 minutes or less. Allergies affect around one in five Americans, accounting for 10% of all doctor's office visits, says Quidel. The worldwide in-vitro allergy testing market is estimated at $150 million.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.